
Eli Lilly's Alzheimer's Drug Approved by FDA, Market Reaction Muted
Eli Lilly's stock did not surge following the FDA approval of its Alzheimer's drug, Kisunla, because the approval was already anticipated and priced into the stock. Investors are more focused on the company's potential in the anti-obesity market with its GLP-1 treatments, which are expected to generate significantly higher revenue.
